Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) was recently identified as a major hydrolase of an endogenous stimulator of interferon genes (STING) agonist, 2′,3′-cyclic guanosine monophosphate–adenosine monophosphate (cGAMP). ENPP1 is a promising therapeutic target in cancer immunotherapy, in which the inhibition of ENPP1 enhances anticancer immunity via STING-mediated innate immune activation. This review highlights the role of ENPP1 in innate immunity and the recent discovery of small molecule ENPP1 inhibitors as immunomodulators in cancer immunotherapy.
This research was supported in part by National Research Foundation of Korea (NRF) grants funded by the Korea government (MSIT) (2020R1C1C1005563 and 2019R1A6A1A11051471).National Research Foundation of Korea, Grant/Award Numbers: 2019R1A6A1A11051471, 2020R1C1C1005563 Funding information
